Skip to content

Biopharma Startups Need $$$ For R&D: That’s Where This Power Stock Comes In

biopharma

Research and development, or R&D, is the lifeblood of the biopharmaceutical industry.

According to the Congressional Budget Office, biopharma companies spend 25% or more of their revenues on R&D of new drugs and products to help save lives.

But startup biopharma companies face a problem: Most don’t have the revenue to reinvest in R&D. That leaves them to look for new capital to fund development.

That’s where this power stock comes in…

The post Biopharma Startups Need $$$ for R&D: That’s Where This Power Stock Comes In originally appeared at Money & Markets.